How Big Pharma Markets to and Profits from a ‘Can’t-Pay-Attention Nation’

<div class="separator" style="clear: both; text-align: center;"></div><div style="margin-left: 1em; margin-right: 1em;"><img alt="" src="http://www.davidicke.com/wordpress/wp-content/uploads/2013/12/adderall_banner.jpg" title="adderall_banner" /></div><br /><br /><span style="font-size: large;">‘What came first: the disorder, the cure, or the marketing campaign to sell both?</span><br /><span style="font-size: large;"><br /></span><span style="font-size: large;">“You’re talking about a product that’s having a major impact on brain chemistry. Parents are very susceptible to this type of stuff.” –Roger Griggs, pharma exec who now objects to ad campaigns</span><br /><span style="font-size: large;"><br /></span><span style="font-size: large;">In the case of medicating a generation of children who were said to be “unusually hyperactive,” the answer to that question is addressed by an in-depth investigation by the New York Times on Monday showing that the meteoric rise of diagnoses of attention deficit hyperactivity disorder (A.D.H.D.)—a trend that spawned a pharmaceutical gold rush over the last twenty years—was, in fact, fueled by an industry-led marketing campaign that targeted struggling children, worried parents, and an army of doctors willing to diagnose and prescribe.</span><br /><br /><span style="font-size: large;">And what’s worse? The deep-pocketed, pill-pushers are now looking to expand.’</span><br /><br /><span style="font-size: large;">Read <a href="http://www.commondreams.org/headline/2013/12/16-0">more... </a></span>

How Big Pharma Markets to and Profits from a ‘Can’t-Pay-Attention Nation’

‘What came first: the disorder, the cure, or the marketing campaign to sell both? “You’re talking about a product that’s having a major impa...

Read more »